Thelansis

 Treatment-resistant depression (TRD) presents a multifaceted clinical challenge influenced by various risk factors. It demands a comprehensive approach that integrates therapeutic strategies. These approaches encompass medication optimization, a combination of antidepressants, switching between antidepressants, and augmentation with non-antidepressant options. Moreover, TRD management involves psychosocial and cultural therapies, along with somatic treatments such as electroconvulsive therapy, deep brain stimulation, magnetic seizure therapy, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and vagus nerve stimulation. ·        According to Thelansis disease modeling data, literature reviews, surveys, and registry analyses, it is estimated that TRD affects approximately 30% to 52% of individuals within the treated MDD patient population.   Thelansis’s “Treatment-Resistant Depression (TRD) Market Outlook...

 Treatment-resistant depression (TRD) is a complex clinical problem caused by multiple risks factors that are targeted by integrated therapeutic strategies, which include optimization of medications, a combination of antidepressants, switching of antidepressants, and augmentation with non-antidepressants, psychosocial and cultural therapies, and somatic therapies including electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy, deep brain stimulation, transcranial direct current stimulation, and vagus nerve stimulation. ·        According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the prevalence of TRD is estimated to be between 30% to 52% of the treated MDD patient population. Thelansis’s “Treatment-Resistant Depression (TRD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epid...